Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

C N Sternberg, H Dumez, H Van Poppel, I Skoneczna, A Sella, G Daugaard, T Gil, J Graham, P Carpentier, F Calabro, L Collette, D Lacombe, EORTC Genitourinary Tract Cancer Group

Abstract

BACKGROUND: This randomized, phase II study assessed the activity of oblimersen sodium, a Bcl-2 antisense oligonucleotide, administered before docetaxel (Taxotere) to patients with castration-resistant prostate cancer.

PATIENTS AND METHODS: Chemotherapy-naive patients with prostate-specific antigen (PSA) progression and testosterone < or = 0.5 ng/ml received docetaxel 75 mg/m2 on day 1 or oblimersen 7 mg/kg/day continuous i.v. infusion on days 1-7 with docetaxel 75 mg/m2 on day 5 every 3 weeks for < or = 12 cycles. Primary end points were confirmed PSA response (Bubley criteria) and major toxic events.

RESULTS: Confirmed PSA response was observed in 46% and 37% of 57 and 54 patients treated with docetaxel and docetaxel-oblimersen, respectively. Partial response (RECIST) was achieved in 18% and 24%, respectively. Oblimersen added to docetaxel was associated with an increase in the incidence of grade > or = 3 fatigue, mucositis, and thrombocytopenia. Major toxic events were reported in 22.8% and 40.7% of patients with docetaxel and docetaxel-oblimersen, respectively.

CONCLUSIONS: The primary end points of the study were not met: a rate of confirmed PSA response >30% and a major toxic event rate <45% were not observed with docetaxel-oblimersen.

Original languageEnglish
JournalAnnals of Oncology
Volume20
Issue number7
Pages (from-to)1264-9
Number of pages6
ISSN0923-7534
DOIs
Publication statusPublished - Jul 2009
Externally publishedYes

Keywords

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Castration
  • Docetaxel
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Prostate-Specific Antigen
  • Prostatic Neoplasms/drug therapy
  • Taxoids/administration & dosage
  • Thionucleotides/administration & dosage
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this